APELLIS PHARMACTDL Valuation
| 1JK Stock | EUR 31.28 0.82 2.55% |
At this time, the firm appears to be overvalued. APELLIS PHARMACTDL 0001 shows a prevailing Real Value of €25.05 per share. The current price of the firm is €31.28. Our model approximates the value of APELLIS PHARMACTDL 0001 from examining the firm fundamentals such as Return On Equity of -5.07, shares owned by insiders of 15.32 %, and Operating Margin of (4.60) % as well as evaluating its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that APELLIS PHARMACTDL's price fluctuation is not too volatile at this time. Calculation of the real value of APELLIS PHARMACTDL 0001 is based on 3 months time horizon. Increasing APELLIS PHARMACTDL's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the APELLIS stock is determined by what a typical buyer is willing to pay for full or partial control of APELLIS PHARMACTDL 0001. Since APELLIS PHARMACTDL is currently traded on the exchange, buyers and sellers on that exchange determine the market value of APELLIS Stock. However, APELLIS PHARMACTDL's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 31.28 | Real 25.05 | Hype 31.28 |
The real value of APELLIS Stock, also known as its intrinsic value, is the underlying worth of APELLIS PHARMACTDL 0001 Company, which is reflected in its stock price. It is based on APELLIS PHARMACTDL's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of APELLIS PHARMACTDL's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of APELLIS PHARMACTDL 0001 helps investors to forecast how APELLIS stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of APELLIS PHARMACTDL more accurately as focusing exclusively on APELLIS PHARMACTDL's fundamentals will not take into account other important factors: APELLIS PHARMACTDL Total Value Analysis
APELLIS PHARMACTDL 0001 is presently estimated to have takeover price of 0 with market capitalization of 5.78 B, debt of 409.63 M, and cash on hands of 599.01 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the APELLIS PHARMACTDL fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 5.78 B | 409.63 M | 599.01 M |
APELLIS PHARMACTDL Investor Information
About 15.0% of the company shares are owned by insiders or employees . The company recorded a loss per share of 7.48. APELLIS PHARMACTDL 0001 had not issued any dividends in recent years. APELLIS PHARMACTDL 0001 is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.APELLIS PHARMACTDL Asset Utilization
One of the ways to look at asset utilization of APELLIS is to check how much profit was generated for every dollar of assets it reports. APELLIS PHARMACTDL 0001 shows a negative utilization of assets of -0.46 percent, losing €0.004647 for each euro of assets held by the firm. Inadequate asset utilization signifies that the company is being less productive with each euro of assets it shows. Put another way, asset utilization of APELLIS PHARMACTDL 0001 shows how discouraging it operates for each euro spent on its assets.APELLIS PHARMACTDL Ownership Allocation
APELLIS PHARMACTDL holds a total of 110.58 Million outstanding shares. The majority of APELLIS PHARMACTDL 0001 outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in APELLIS PHARMACTDL 0001 to benefit from reduced commissions. Thereupon, institutional investors are subject to a different set of regulations than regular investors in APELLIS PHARMACTDL. Please pay attention to any change in the institutional holdings of APELLIS PHARMACTDL 0001 as this could imply that something significant has changed or is about to change at the company. Also note that nearly four million nine hundred fifty-three thousand eight hundred five invesors are currently shorting APELLIS PHARMACTDL expressing very little confidence in its future performance.APELLIS PHARMACTDL Profitability Analysis
The company reported the revenue of 113.05 M. Net Loss for the year was (460.28 M) with loss before overhead, payroll, taxes, and interest of (253.92 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates APELLIS PHARMACTDL's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in APELLIS PHARMACTDL and how it compares across the competition.
About APELLIS PHARMACTDL Valuation
The stock valuation mechanism determines APELLIS PHARMACTDL's current worth on a weekly basis. Our valuation model uses a comparative analysis of APELLIS PHARMACTDL. We calculate exposure to APELLIS PHARMACTDL's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of APELLIS PHARMACTDL's related companies.Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. APELLIS PHARMACT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 445 people.
8 Steps to conduct APELLIS PHARMACTDL's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates APELLIS PHARMACTDL's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct APELLIS PHARMACTDL's valuation analysis, follow these 8 steps:- Gather financial information: Obtain APELLIS PHARMACTDL's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine APELLIS PHARMACTDL's revenue streams: Identify APELLIS PHARMACTDL's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research APELLIS PHARMACTDL's industry and market trends, including the size of the market, growth rate, and competition.
- Establish APELLIS PHARMACTDL's growth potential: Evaluate APELLIS PHARMACTDL's management, business model, and growth potential.
- Determine APELLIS PHARMACTDL's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate APELLIS PHARMACTDL's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for APELLIS Stock analysis
When running APELLIS PHARMACTDL's price analysis, check to measure APELLIS PHARMACTDL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy APELLIS PHARMACTDL is operating at the current time. Most of APELLIS PHARMACTDL's value examination focuses on studying past and present price action to predict the probability of APELLIS PHARMACTDL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move APELLIS PHARMACTDL's price. Additionally, you may evaluate how the addition of APELLIS PHARMACTDL to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |